SAN DIEGO, Sept. 12, 2014 /PRNewswire/ -- Volcano
Corporation (NASDAQ: VOLC), a leading company focused on
improving patient and economic outcomes on a global basis by
developing and delivering innovative minimally invasive coronary
and peripheral visualization, physiology diagnostics and
therapies, announced today that it will be launching novel
interventional precision guidance tools at the 27th Annual
Transcatheter Cardiovascular Therapeutics (TCT) scientific
symposium, being held in Washington, DC from September 13 to
September 17.
Enhancing coronary imaging, the SyncVision®
co-registration system will be shown at TCT for the first time
since its Limited Market Release. SyncVision®
features a live, on-line image processing workstation for coronary
catheterizations that allows physicians to simultaneously navigate
on both an angiogram and an IVUS image in a single correlated
view. Attendees who visit the booth will experience hands-on
how SyncVision® is designed to combine the functionality
of the angiographic road map with the precision of the intra-vessel
IVUS image. The product is currently installed in select
institutions in the United States,
Europe, Japan and China and will be featured in case
demonstrations during the scientific sessions.
As a first for Volcano, the SyncVision® 'Angio Plus'
suite of tools not only enhances the IVUS image, but augments the
angiogram itself by offering image enhancement and stabilization
tools. Physicians no longer have to use a Volcano IVUS catheter or
pressure wire to augment the precision of the angiogram, enabling
Volcano to offer value in significantly more cases.
The company also announces the full market release of its
proprietary iFR® Modality in Meet the Expert
sessions at its booth and live case transmissions. The
iFR® Modality is a physiologic measurement
performed using the same pressure wires and equipment utilized in
cath labs for Fractional Flow Reserve (FFR), which avoids injection
of hyperemic agents into the patient that can induce stress to the
heart. This allows for a meaningful, lesion-specific
assessment in seconds by amplifying the resting pressure waveform.
The technology has been studied in over 4,000 patients, cleared by
the FDA in March, 2014 and is now installed in over 700 hospitals
in all major geographies.
"Volcano is the clear market leader in coronary imaging and
physiology and will continue to be present for physicians and for
patients, providing more precise tools to guide these important
therapies," said Scott Huennekens, president and chief
executive officer of Volcano Corp. "We believe the addition of the
iFR® Modality and SyncVision® co-registration
tools will allow us to add precision to everyday tools, with
workflows that are fast and simple enough to be adopted in the
busiest of cath labs. TCT is a great week for physicians and
hospital team members to see these tools live for themselves and
plan how to make them a part of their cath lab routine."
About Volcano Corporation
Through its multi-modality platform, Volcano
Corporation is the global leader in intravascular imaging for
coronary and peripheral applications, and physiology. The company
also offers a suite of peripheral therapeutic devices. The
company's broad range of technologies makes imaging and therapy
simpler, more informative and less invasive and offers physicians
and their patients around the world with industry-leading tools
that aid diagnosis and guide and provide therapy. Founded in
cardiovascular care and expanding into other specialties, Volcano
is focused on improving patient and economic outcomes. For more
information, visit the company's website
at www.volcanocorp.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical
facts may be considered "forward-looking statements." including
statements regarding the potential benefits of the products and
technologies described above. Forward-looking statements are based
on management's current expectations and are subject to risks and
uncertainties which may cause Volcano's results to differ
materially and adversely from the statements contained herein. Some
of the potential risks and uncertainties that could cause actual
results to differ include the pace and extent of market adoption of
the company's products and technologies;; the company's ability to
obtain or maintain patent or other proprietary intellectual
property protection; competition in general; government, industry
and general public pricing pressures; unexpected manufacturing
issues; product introductions; unexpected new data, safety and
technical issues; market conditions; and other risks inherent to
medical device development and commercialization. These and
additional risks and uncertainties are more fully described in
Volcano's filings made with the Securities and Exchange
Commission, including our recent quarterly report on Form
10-Q. Undue reliance should not be placed on forward-looking
statements which speak only as of the date they are made. Volcano
undertakes no obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
Logo -
http://photos.prnewswire.com/prnh/20140912/145645
SOURCE Volcano Corporation